Viamet Pharmaceuticals Reports Additional Positive Interim Results Of Phase 2 Studies Of VT-1161 With Moderate To Severe Interdigital Tinea Pedis
7/11/2014 11:04:25 AM
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Viamet Pharmaceuticals, Inc. today reported additional positive interim results from its ongoing Phase 2a study of VT-1161, the Company’s lead novel, oral antifungal compound, in patients with moderate to severe interdigital tinea pedis, commonly known as athlete’s foot. The additional data being reported today are for the highest dose of VT-1161 in the study. These data provide additional strong evidence of clinical antifungal activity and a favorable safety profile for VT-1161 in treating human infections due to dermatophytes. Based on these positive results, the company expects to begin Phase 2b clinical trials for VT-1161 in patients with onychomycosis in the second half of 2014.
Help employers find you! Check out all the jobs and post your resume.
comments powered by